◆英語タイトル:Juno Therapeutics Inc - Strategic SWOT Analysis Review
◆商品コード:DATA904C3065
◆発行会社(調査会社):
GlobalData
◆発行日:2018年8月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Juno Therapeutics Inc – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights
Juno Therapeutics Inc (Juno) is a clinical-stage company that develops novel cellular immunotherapies. The company formulates cell-based cancer immunotherapies based on platforms such as chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to identify and kill cancer cells. It develops CD19 CAR and WT-1 TCR clinical programs which include numerous product candidates in clinical development for several hematologic malignancies in adults and children. Juno offers CAR and TCR product candidates targeting multiple cancer types. The company is evaluating its pipeline candidates for the treatment of relapsed/refractory (r/r) Chronic Lymphocytic Leukemia (CLL), r/r B-Cell Non-Hodgkin’s Lymphoma (NHL); r/r Acute Lymphoid Leukemia (ALL). It works in collaboration with various cancer centers. Juno is headquartered in Seattle, Washington, the US.
Juno Therapeutics Inc Key Recent Developments
Jan 12,2018: Juno Therapeutics Investigation By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. – JUNO
Jan 05,2018: Juno Therapeutics Names Cindy Elkins as Chief Information Officer
Dec 20,2017: Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership
Nov 27,2017: Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO
Nov 01,2017: Juno Therapeutics Reports Third Quarter 2017 Financial Results
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Juno Therapeutics Inc – Key Facts 5
Juno Therapeutics Inc – Key Employees 6
Juno Therapeutics Inc – Key Employee Biographies 7
Juno Therapeutics Inc – Major Products and Services 8
Juno Therapeutics Inc – History 9
Juno Therapeutics Inc – Company Statement 11
Juno Therapeutics Inc – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Joint Venture 14
Section 2 – Company Analysis 15
Company Overview 15
Juno Therapeutics Inc – Business Description 16
R&D Overview 16
Juno Therapeutics Inc – SWOT Analysis 17
SWOT Analysis – Overview 17
Juno Therapeutics Inc – Strengths 17
Juno Therapeutics Inc – Weaknesses 18
Juno Therapeutics Inc – Opportunities 19
Juno Therapeutics Inc – Threats 20
Juno Therapeutics Inc – Key Competitors 21
Section 3 – Company’s Lifesciences Financial Deals and Alliances 22
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 22
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 23
Juno Therapeutics Inc, Recent Deals Summary 24
Section 4 – Company’s Recent Developments 25
Jan 12, 2018: Juno Therapeutics Investigation By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. – JUNO 25
Jan 05, 2018: Juno Therapeutics Names Cindy Elkins as Chief Information Officer 26
Dec 20, 2017: Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership 27
Nov 27, 2017: Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO 28
Nov 01, 2017: Juno Therapeutics Reports Third Quarter 2017 Financial Results 29
Oct 12, 2017: Biomarkers May Help Identify Patients at Increased Risk of Neurotoxicity From CD19 CAR T-cell Therapy 32
Oct 11, 2017: New insights into CAR T-cell therapy’s potential side effects 33
Sep 21, 2017: Juno Therapeutics Opens New Headquarters and Research Center 35
Aug 09, 2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment 36
Aug 03, 2017: Juno Therapeutics Reports Second Quarter 2017 Financial Results 37
Section 5 – Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List of Tables
Juno Therapeutics Inc, Key Facts 5
Juno Therapeutics Inc, Key Employees 6
Juno Therapeutics Inc, Key Employee Biographies 7
Juno Therapeutics Inc, Major Products and Services 8
Juno Therapeutics Inc, History 9
Juno Therapeutics Inc, Subsidiaries 14
Juno Therapeutics Inc, Joint Venture 14
Juno Therapeutics Inc, Key Competitors 21
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 22
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 23
Juno Therapeutics Inc, Recent Deals Summary 24
List of Figures
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 22
Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 23